{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0171","paramType":"Hazard Ratio (HR)","paramValue":"0.78","statisticalComment":"Stratified weighted log-rank test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.63","upperLimit":"26.38","value":"21.72"},{"groupId":"OG001","lowerLimit":"14.72","upperLimit":"22.44","value":"18.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"304"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"description":"This measure looks at how long people who are able to receive cisplatin (a type of chemotherapy) live after being placed into a treatment group in the sub-study.\n\nOverall Survival (OS) is defined as the time between the date a participant is randomized (assigned to a treatment group) and the date of death from any cause. For participants without documentation of death, OS will be measured up to the last date the participant was known to be alive. If a participant was randomized but had no follow-up information, OS will be counted from the date of randomization.\n\nThis helps to understand if the treatment can help people who are eligible for cisplatin chemotherapy live longer.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Nivolumab 360 mg in combination with Standard of Care treatment every 3 weeks (Q3W) for up to 6 cycles followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Sub-study","id":"OG000","title":"Treatment 3"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Sub-study","id":"OG001","title":"Treatment 4"}],"paramType":"MEDIAN","populationDescription":"All Cisplatin-eligible Randomized Participants - Sub-study","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)","title":"Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study","type":"PRIMARY","unitOfMeasure":"Months"}